Prospective Multicenter Registry Study of Multiple System Atrophy in China

NCT07644013 | Recruiting

• 1 other identifier: MSARegistryStudy-20250302
• Study Type: observational
• Target: 214
• Locations: 1 country
• Sites: 1

Brief Summary

Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease characterized by variable combinations of parkinsonism, cerebellar ataxia, and autonomic dysfunction. Existing natural history studies from North America, Europe, and Japan suggest that clinical phenotypes and disease progression may differ across populations. However, comprehensive multicenter prospective data from Chinese patients with multiple system atrophy remain limited. This prospective multicenter registry study aims to describe the clinical characteristics, longitudinal progression, and outcomes of Chinese patients with multiple system atrophy, to identify factors associated with disease progression and prognosis, and to establish a longitudinal cohort for future biomarker validation and clinical trial design.

Conditions

Multiple System Atrophy; Parkinson's Disease; Atypical Parkinsonism

Keywords

Multiple system atrophy; natural history; prospective cohort; multicenter registry; disease progression; neuroimaging; biomarkers; alpha-synuclein

Outcome Measures

Primary Outcomes (1)

• Change in disease severity

  Change in disease severity as measured by the Unified Multiple System Atrophy Rating Scale over longitudinal follow-up.

  Baseline to up to 36 months after enrollment.

Study Arms (3)

MSA

PD

HC

Healthy control / Control without neurodegenerative diseases

Eligibility Criteria

• Age: 40 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with MSA or PD who visited the outpatient department or wards of tertiary hospitals. Those who voluntarily participated, along with the family members of healthy individuals without neurodegenerative diseases, served as healthy controls.

You may qualify if:

• Patients with clinically established or clinically probable multiple system atrophy according to the 2022 Movement Disorder Society diagnostic criteria; or
• Patients with clinically established or clinically probable Parkinson disease according to the Movement Disorder Society diagnostic criteria; or
• Healthy controls or controls without hereditary or neurodegenerative diseases who voluntarily agree to participate.
• Age between 40 and 75 years.
• Ability to provide informed consent or availability of a legally authorized representative when applicable.

You may not qualify if:

• Parkinsonism that cannot be classified as Parkinson disease or multiple system atrophy at the time of evaluation.
• Clinical suspicion or diagnosis of other atypical parkinsonian syndromes, including progressive supranuclear palsy, dementia with Lewy bodies, or corticobasal syndrome.
• Secondary parkinsonism due to intracranial space-occupying lesions, normal pressure hydrocephalus, drug-induced parkinsonism, or other identifiable causes.
• Comorbid diseases that may substantially affect autonomic function, such as diabetic peripheral neuropathy or amyloidosis.
• Refusal to participate in the study or refusal to undergo routine clinical evaluations for parkinsonian syndromes.
• Psychiatric or behavioral abnormalities that preclude reliable clinical data collection or scale-based assessment.

Sponsors & Collaborators

• Peking University First Hospital: lead

Study Sites (1)

Peking University First Hospital

Beijing, Beijing Municipality, 100034, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Blood, urine, saliva, and, when clinically indicated and consented, cerebrospinal fluid and skin biopsy samples may be collected. Blood samples may be processed for serum, plasma, and DNA. Saliva samples may be used for alpha-synuclein seeding activity assays, and urine samples can be used for metabolomic analysis as well as proteomic analysis.

MeSH Terms

Conditions

Multiple System Atrophy; Parkinson Disease; Disease Progression; Parkinson Disease 4, Autosomal Dominant Lewy Body

Condition Hierarchy (Ancestors)

Primary Dysautonomias; Autonomic Nervous System Diseases; Nervous System Diseases; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Parkinsonian Disorders; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Zhaoxia Wang, MD

  Department of Neurology, Peking University First Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yunchuang Sun, MD

CONTACT

sychuang0805@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 6 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 8, 2026
• First Posted: June 12, 2026
• Study Start: June 1, 2025
• Primary Completion (Estimated): December 31, 2029
• Study Completion (Estimated): June 30, 2030
• Last Updated: June 12, 2026

Record last verified: 2026-05

Locations

CN (1)